-
. Preferred Qualifications Experience with human iPSC culture and neuronal differentiation, organoids, or related neural model systems. Experience with next-generation sequencing library preparation and multi
-
allograft rejection/failure is highly desirable. The approaches are founded on interpretation of large data sets from human genome level sequence data and/or mouse cell type specific transcriptome sequence
-
arteriovenous malformations, using patient cohorts and surgical specimens together with whole exome sequencing and a range of transcriptomic, epigenomic, and spatial methods. The successful candidate will analyze
-
samples. The lab seeks to uncover new therapeutic targets in cancer by bridging single-cell sequencing with high-throughput immune/cancer cell co-culture screens (PMID: 33483338, PMID: 40799546, PMID
-
approaches such as non-coding CRISPR screens, the Massively Parallel Reporter Assay (MPRA), saturation mutagenesis, and synthetic sequence design, alongside machine-learning models of regulatory grammar
-
of epigenetics of psychiatric traits; and studies of whole genome sequence in psychiatric traits. A NIDA-funded study concentrates on cannabis use genetics and PRS prediction of response to THC in a laboratory
-
with CRISPR genome engineering Expertise in eukaryotic gene regulation or RNA biology Familiarity with next-generation sequencing approaches and transcriptome analysis Experience with fluorescence
-
, or population genetics Deep learning for sequence, EHR, or imaging data High-performance and GPU computing environments Excellent candidates from adjacent quantitative fields are encouraged to apply. The Research
-
experimental approaches such as non-coding CRISPR screens, the Massively Parallel Reporter Assay (MPRA), saturation mutagenesis, and synthetic sequence design, alongside machine-learning models of regulatory